Ensign Peak Advisors
EFTR

Ensign Peak Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Ensign Peak Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,945
Closed -$474K – 1748
2024
Q1 		$474K Buy
+32,945
New +$394K ﹤0.01% 1635

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Ensign Peak Advisors's EFTR Position: Q2 2024 in Review

Ensign Peak Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2024, closing a stake of 32,945 shares — an estimated $474K sold.

Ensign Peak Advisors first reported a position in EFTR in Q1 2024 and held it in 1 quarter. The position peaked at $474K in Q1 2024. 18 funds tracked by Wall St. Rank hold EFTR as of Q2 2024.

  • Ensign Peak Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 32,945 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $474K.
  • Ensign Peak Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Ensign Peak Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $474K in Q1 2024.
  • 18 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Ensign Peak Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.